Home » Company Seeking FDA Approval of Medicine for Rare Genetic Disease
Company Seeking FDA Approval of Medicine for Rare Genetic Disease
The acquisition of Chenofalk is important not only to ensure continued supply in Germany, but Sigma-Tau Pharmaceuticals also intends to accumulate the appropriate clinical and regulatory documentation required to support the filing of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the use of chenodeoxycholic acid (CDCA) in the treatment of Cerebrotendinous Xanthomatosis (CTX) disease.
MarketWatch
MarketWatch
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May